Anthony DiGiandomenico
Independent DirectorMr. Anthony DiGiandomenico is Director of ClearSign Technologies Corporation from May 22, 2025. He has been Independent Director at Illumination Acquisition Corp I since February 26, 2026. He has been working with and enabling investment into early-stage disruptive technologies for most of his career. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology and renewable energy spaces. Mr. DiGiandomenico serves as the Chief of Transactions and Director of MDB Capital Holdings, LLC, a broker-dealer and financial advisory firm based in Dallas, Texas, which he co-founded in 1997 as MDB Capital Group, LLC. He serves as Director of Cue Biopharma, Inc., that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders from January 2016 to October 2019. He has been Chief of Transactions at MDB Capital Holdings, LLC since its inception on August 10, 2021 and serves as its Co-Founder and Head of New Venture Discovery. Mr. DiGiandomenico has been a Director at eXoZymes, Inc. (formerly known as Invizyne Technologies, Inc.) since April 2019. He served as a Director of Provention Bio, Inc. from January 2017 until May 2020 and has been an Independent Director of ENDRA Life Sciences Inc. since 2013. He co-founded MDB Capital Group LLC in December 1996 and has been a Partner at MDB Capital, focusing on corporate finance and capital formation for growth-oriented companies. His career in the investment industry began with the formation of MDB, where he has participated in all areas of corporate finance including private capital, public offerings, PIPEs, business consulting, strategic planning and mergers and acquisitions. Mr. DiGiandomenico has also worked on a wide range of transactions for growth-oriented companies in biotechnology, nutritional supplements, manufacturing and entertainment industries. He possesses financial expertise, general business acumen and significant executive leadership experience. Previously, he served as the Chief Financial Officer and Principal Accounting Officer of Orion Acquisition Corp. II until December 17, 2004 and as President and Chief Executive Officer of the Digian Company from 1988 to 1996. He has financed real estate projects and his project and personnel management experience has proven invaluable to the companies MDB has invested in. Mr. DiGiandomenico holds a Bachelor of Science Degree in Finance from the University of Colorado and a Master of Business Administration from the Haas School of Business at the University of California, Berkeley.
Positions
- Company NameClearSign Technologies CorporationStock CodeCLIRPositionIndependent DirectorColleagues
- CJColin James DellerCEO & Director
- BHBrent HindsCFO & Corporate Secretary
- MMMatthew MartinChief Technology Officer
- SMStephen Michael SockSenior Vice President of Business Development
- GTGil Todd SilvaIndependent Director
- ADAnthony DiGiandomenicoIndependent Director
- LJLouis J. BaseneseIndependent Director
- LMLarry M. SaddlerDirector
- Company NameENDRA Life Sciences Inc.Stock CodeNDRAPositionIndependent Director
- Company NameMDB Capital Holdings, LLCStock CodeMDBHPositionCo-Founder, Head of New Venture Discovery & DirectorColleagues
- CAChristopher A. MarlettCo-Founder, CEO & Chairman
- MHMohammad HayatHead of Corporate Development, Chief Legal Officer & Director
- ADAnthony DiGiandomenicoCo-Founder, Head of New Venture Discovery & Director
- GHGeorge H. BrandonPresident, Head of Community Development & Director
- JWJeremy William JamesChief Financial Officer
- DTDaniel Thomas TorpeyIndependent Director
- Company NameIllumination Acquisition Corp IStock CodeILLUPositionIndependent DirectorRelated Securities
